Thursday, September 20, 2012
Publication and contact
Killer cell lectin-like receptor subfamily K member
ligands as markers to predict response to anti-CTLA-4
therapies and guide selection of radiation therapy regimens
Mouse studies suggest
levels of NKG2D ligands could be used as a marker to predict patient
responsiveness to anti-CTLA-4 therapies and help guide selection of radiation
therapy regimens. In mice bearing poorly immunogenic tumors, an anti-CTLA-4
mAb plus radiotherapy led to greater T cell contact time with tumor cells and
tumor regression than either therapy alone. In the xenograft mice treated
with the combination therapy, an anti-NKG2D mAb reversed the increased T cell
contact time and tumor regression, suggesting ligand-NKG2D interactions are
required for anti-CTLA-4 and radiotherapy synergy. Next steps include
clinical trials to determine the best radiation therapy regimens to use with
anti-CTLA-4 therapies in patients with melanoma.
Squibb Co. markets the human anti-CTLA-4 mAb Yervoy
to treat melanoma. The mAb also is in Phase III testing for prostate cancer
and Phase II testing for lung cancer, non-small cell lung cancer (NSCLC),
pancreatic cancer and solid tumors.
Inc. and AstraZeneca
plc have the human anti-CTLA-4 mAb tremelimumab
in Phase II testing for liver cancer and solid tumors and in Phase I for
melanoma and prostate cancer (see Strategic synergy, page 8).
Published online Sept. 20, 2012
Ruocco, M.G. et al. J.
Clin. Invest.; published online Sept. 4, 2012;
Contact: Sandra Demaria,
New York University School of Medicine, New York, N.Y.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]